TIVZ SD Pill - yellow capsule/oblong, 14mm
Generic Name: tivozanib
Pill with imprint TIVZ SD is Yellow, Capsule/Oblong and has been identified as Fotivda 1.34 mg. It is supplied by AVEO Oncology.
Fotivda is used in the treatment of Renal Cell Carcinoma and belongs to the drug class VEGF/VEGFR inhibitors. Fotivda 1.34 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for TIVZ SD
Fotivda
- Generic Name
- tivozanib
- Imprint
- TIVZ SD
- Strength
- 1.34 mg
- Color
- Yellow
- Size
- 14.00 mm
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- VEGF/VEGFR inhibitors
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- AVEO Oncology
- National Drug Code (NDC)
- 45629-0134
See also:
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Botox
Botox is used cosmetically to reduce facial lines and wrinkles and for medical purposes for ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Lenvima
Lenvima (lenvatinib) is used to treat thyroid cancer, advanced renal cell carcinoma, hepatocellular ...
Cabometyx
Cabometyx is used to treat advanced kidney cancer, liver cancer, thyroid cancer, and pancreatic and ...
Afinitor
Afinitor prevents the growth of cancer cells and is used to treat advanced kidney cancer. Learn ...
Lenvatinib
Lenvatinib is used to treat thyroid cancer, kidney cancer, liver cancer, and advanced endometrial ...
Everolimus
Everolimus (Afinitor, Afinitor Disperz, Zortress) belongs to a class of drugs called kinase ...
More about Fotivda (tivozanib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: VEGF/VEGFR inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.